8 PIPELINE ELI LILLY AND COMPANY Updated January 27, 2020 Phase 1 Phase 2 NME NME Angiopoietin 3/8 mAb CVD Automated Insulin Diabetes DACRA-089 Diabetes Delivery System GDF 15 Agonist Diabetes Basal Insulin-FC Diabetes GGG Tri-agonist Diabetes CD200R mAb Agonist Immunology GLP-1 Receptor NPA Diabetes D1 PAM Dementia Oxyntomodulin Diabetes Donanemab (N3pG Aβ mAb) Alzheimer’s GIP/GLP Co-agonist Peptide Diabetes Zagotenemab (Tau mAb) Alzheimer’s BAFF/IL-17 Bispecific Immunology NILEX BTLA mAb Agonist Immunology CXCR1/2L mAb Immunology Tirzepatide Nonalcoholic steatohepatitis IL-2 Conjugate Immunology (NASH) IL-33 mAb Immunology Olaratumab Pancreatic PD-1 mAb Agonist Immunology Cancer D1 PAM II Dementia Abemaciclib Prostate Cancer O-GlcNAcase Inhibitor Alzheimer’s Tau Morphomer Alzheimer’s Aurora A Kin Inhibitor Cancer BTK Inhibitor Cancer Cancer (undisclosed) Cancer CD226 Agonist Cancer ERK Inhibitor Cancer KRAS G12C Inhibitor Cancer PD-1/PD-L1 Bispecific Cancer SERD Cancer PACAP38 mAb Pain SSTR4 Agonist Pain TrpA1 Antagonist Pain KEY ADVANCES IN OUR INNOVATION STRATEGY Tirzepatide Lebrikizumab A dual GIP and GLP-1 receptor agonist with the potential for An IL-13 antibody added via the acquisition of Dermira joins game-changing reductions in A1C and body weight in people baricitinib, an oral JAK 1/JAK 2 inhibitor, as a second approach with type 2 diabetes. It’s also being studied in obesity and NASH, being studied to help people suffering from atopic dermatitis. an inflammatory condition caused by liver fat.